Related Experiment Videos
Randomized study comparing chemotherapy with and without estrogen priming in advanced breast-cancer
Y Horn1, N Walach, A Pavlotsky
1UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143. UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143.
International Journal of Oncology
|May 14, 2011
Summary
Estrogen priming did not improve chemotherapy outcomes for advanced breast cancer patients. This study found no significant difference in toxicity or response rates between combination chemotherapy with and without estrogen priming.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced breast cancer treatment often involves combination chemotherapy.
- Estrogen priming is a potential strategy to enhance chemotherapy efficacy.
Purpose of the Study:
- To evaluate if estrogen priming improves outcomes in advanced breast cancer patients receiving combination chemotherapy.
- To assess the impact of estrogen priming on chemotherapy toxicity and response rates.
Main Methods:
- A randomized trial comparing combination chemotherapy with (E+) and without (E-) estrogen priming.
- Both arms received Adriamycin + Vincristine alternating with Cytoxan + Methotrexate + Fluorouracil every 6 weeks.
- Estrogen priming involved oral estradiol and estriol administration.
Main Results:
- Objective response rates were similar: 79% in the E+ arm versus 73% in the E- arm.
- Complete response rates were 11% (E+) and 9% (E-), with partial response rates of 68% (E+) and 64% (E-).
- Estrogen priming did not increase chemotherapy-related toxicity.
Conclusions:
- Estrogen priming did not enhance the palliative benefit or toxicity profile of combination chemotherapy in advanced breast cancer.
- Further research may be needed to explore alternative roles for estrogen priming in breast cancer treatment.
